115 related articles for article (PubMed ID: 24061864)
1. Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program.
Chen R; Li J; Hu WW; Wang ML; Zou SL; Miao LY
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1111-23. PubMed ID: 24061864
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.
Urien S; Lokiec F
Br J Clin Pharmacol; 2004 Jun; 57(6):756-63. PubMed ID: 15151521
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis.
Li J; Chen R; Ji M; Zou SL; Zhu LN
Cancer Chemother Pharmacol; 2015 Sep; 76(3):651-5. PubMed ID: 26093951
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients.
Urien S; Brain E; Bugat R; Pivot X; Lochon I; Van ML; Vauzelle F; Lokiec F
Cancer Chemother Pharmacol; 2005 Jan; 55(1):55-60. PubMed ID: 15258698
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of cisplatin in adult cancer patients.
de Jongh FE; Gallo JM; Shen M; Verweij J; Sparreboom A
Cancer Chemother Pharmacol; 2004 Aug; 54(2):105-12. PubMed ID: 15127229
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
8. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
de Jongh FE; Verweij J; Loos WJ; de Wit R; de Jonge MJ; Planting AS; Nooter K; Stoter G; Sparreboom A
J Clin Oncol; 2001 Sep; 19(17):3733-9. PubMed ID: 11533095
[TBL] [Abstract][Full Text] [Related]
9. [Population pharmacokinetics applied to optimising cisplatin doses in cancer patients].
Ramón-López A; Escudero-Ortiz V; Carbonell V; Pérez-Ruixo JJ; Valenzuela B
Farm Hosp; 2012; 36(5):392-402. PubMed ID: 22402361
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program.
Nagai N; Ogata H; Wada Y; Tsujino D; Someya K; Ohno T; Masuhara K; Tanaka Y; Takahashi H; Nagai H; Kato K; Koshiba Y; Igarashi T; Yokoyama A; Kinameri K; Kato T; Kurita Y
J Clin Pharmacol; 1998 Nov; 38(11):1025-34. PubMed ID: 9824784
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
13. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL
Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?
Minami H; Ohe Y; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Nishiwaki Y; Nokihara H; Sekine I; Saijo N; Hanada K; Ogata H
J Clin Oncol; 2004 Jul; 22(14):2901-8. PubMed ID: 15254059
[TBL] [Abstract][Full Text] [Related]
15. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
[TBL] [Abstract][Full Text] [Related]
17. A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
Wakelee HA; Middleton G; Dunlop D; Ramlau R; Leighl N; Hao D; Lopez-Anaya A; Zatloukal P; Jacobs CD
Cancer Chemother Pharmacol; 2012 Mar; 69(3):815-24. PubMed ID: 22057854
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients.
Srinivasan M; Chaturvedula A; Fossler MJ; Patil A; Gota V; Prabhash K
J Clin Pharmacol; 2019 Sep; 59(9):1216-1224. PubMed ID: 30973978
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
Thai HT; Veyrat-Follet C; Mentré F; Comets E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):167-80. PubMed ID: 23673444
[TBL] [Abstract][Full Text] [Related]
20. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]